Region Genetic Association Analysis of Breast Cancer Patients With and Without Persistent Postsurgical Neuropathic Pain,” ...

The optimal allogeneic dendritic cell for stimulating self MHC-restricted anti-tumor responses is probably one that is incompatible at one HLA-DR allele with the patient (for direct ...

The major bottleneck is finding targets that are uniquely and homogeneously expressed by cancer cells. Another challenge is that TCR therapeutics must be specific for the target antigen and also ...

Image Credit: CI Photos/Shutterstock.com Immune checkpoint inhibitors, cancer vaccines, and other immunotherapy approaches ...

The Phase II trial examined the therapeutic cancer vaccine Tedopi in combination with chemotherapy drug combination FOLFIRI.

HLA-typing is a simple and widely available test. Tumor Grade: BriaCell has noted clinical benefit in its patients with grade I and grade II tumors, suggesting another subgroup of patients for ...

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

This is a cancer peptide vaccine that stimulates the patient’s immune system by targeting four novel TAAs restricted to human leukocyte antigen A2 (HLA-A2) that are shared across many types of ...

A research team led by Prof. SUN Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, along with collaborators from the Agency for Science, ...

they bind to tumor antigens. This can increase receptor sensitivity while reducing cytotoxicity and T cell exhaustion observed with a CAR. 11,12 (8) Synthetic TCR antigen receptor/HLA-independent TCR ...

Plans to file an investigational new drug (IND) application for TSC-102-A0301, a TCR-T targeting CD45 on HLA-A*03:01, in the second half of 2025. Solid Tumor Program: TScan continues to expand the ...